Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
73.33 USD | +1.85% | +11.70% | +2.75% |
Apr. 18 | Intra-Cellular Therapies Prices $500 Million Stock Offering | MT |
Apr. 17 | Goldman Sachs Adjusts Price Target on Intra-Cellular Therapies to $77 From $67, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.75% | 7.51B | |
-5.99% | 84.46B | |
+2.76% | 40.85B | |
-25.59% | 27.69B | |
+53.61% | 24.28B | |
-7.58% | 17.09B | |
-33.74% | 13.67B | |
-16.44% | 11.86B | |
-11.19% | 11.79B | |
-2.25% | 8.07B |
- Stock Market
- Equities
- ITCI Stock
- News Intra-Cellular Therapies, Inc.
- Intra Cellular Therapies : RBC Boosts Price Target on Intra-Cellular Therapies to $47 From $44, Maintains Outperform Rating